Skip to main content
. 2019 Jan 1;10(1):17–29. doi: 10.18632/oncotarget.26523

Figure 4. Case example of sustained partial remission to immune checkpoint blockade.

Figure 4

CT scans of a 70-year old patient with small cell NEPC with minor adenocarcinoma component, Ki67 85 %. After direct progression to PE, the patient was treated with 4 cycles of dual immune checkpoint blockade with ipilimumab+nivolumab, following nivolumab maintenance therapy. He showed a very good PR for more than 6 months.